These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 15261707)

  • 21. The use of venlafaxine in the treatment of major depression and major depression associated with anxiety: a dose-response study. Venlafaxine Investigator Study Group.
    Khan A; Upton GV; Rudolph RL; Entsuah R; Leventer SM
    J Clin Psychopharmacol; 1998 Feb; 18(1):19-25. PubMed ID: 9472838
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Use of antidepressant drugs in schizophrenic patients with depression].
    Micallef J; Fakra E; Blin O
    Encephale; 2006; 32(2 Pt 1):263-9. PubMed ID: 16910628
    [TBL] [Abstract][Full Text] [Related]  

  • 23. International Study to Predict Optimized Treatment for Depression (iSPOT-D), a randomized clinical trial: rationale and protocol.
    Williams LM; Rush AJ; Koslow SH; Wisniewski SR; Cooper NJ; Nemeroff CB; Schatzberg AF; Gordon E
    Trials; 2011 Jan; 12():4. PubMed ID: 21208417
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Antidepressant response trajectories and quantitative electroencephalography (QEEG) biomarkers in major depressive disorder.
    Hunter AM; Muthén BO; Cook IA; Leuchter AF
    J Psychiatr Res; 2010 Jan; 44(2):90-8. PubMed ID: 19631948
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cost and effectiveness of venlafaxine extended-release and selective serotonin reuptake inhibitors in the acute phase of outpatient treatment for major depressive disorder.
    Trivedi MH; Wan GJ; Mallick R; Chen J; Casciano R; Geissler EC; Panish JM
    J Clin Psychopharmacol; 2004 Oct; 24(5):497-506. PubMed ID: 15349005
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Once-daily venlafaxine extended release (XR) compared with fluoxetine in outpatients with depression and anxiety. Venlafaxine XR 360 Study Group.
    Silverstone PH; Ravindran A
    J Clin Psychiatry; 1999 Jan; 60(1):22-8. PubMed ID: 10074873
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Venlafaxine extended-release for depression following spinal cord injury: a randomized clinical trial.
    Fann JR; Bombardier CH; Richards JS; Wilson CS; Heinemann AW; Warren AM; Brooks L; McCullumsmith CB; Temkin NR; Warms C; Tate DG;
    JAMA Psychiatry; 2015 Mar; 72(3):247-58. PubMed ID: 25607727
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Two items on the Hamilton Depression rating scale are effective predictors of remission: comparison of selective serotonin reuptake inhibitors with the combined serotonin/norepinephrine reuptake inhibitor, venlafaxine.
    Silverstone PH; Entsuah R; Hackett D
    Int Clin Psychopharmacol; 2002 Nov; 17(6):273-80. PubMed ID: 12409680
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Consistent superiority of selective serotonin reuptake inhibitors over placebo in reducing depressed mood in patients with major depression.
    Hieronymus F; Emilsson JF; Nilsson S; Eriksson E
    Mol Psychiatry; 2016 Apr; 21(4):523-30. PubMed ID: 25917369
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Venlafaxine XR demonstrates higher rates of sustained remission compared to fluoxetine, paroxetine or placebo.
    Shelton C; Entsuah R; Padmanabhan SK; Vinall PE
    Int Clin Psychopharmacol; 2005 Jul; 20(4):233-8. PubMed ID: 15933485
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Milnacipran and venlafaxine at flexible doses (up to 200 mg/d) in the outpatient treatment of adults with moderate-to-severe major depressive disorder: a 24-week randomised, double blind exploratory study].
    Olié JP; Gourion D; Montagne A; Rostin M; Poirier MF
    Encephale; 2009 Dec; 35(6):595-604. PubMed ID: 20004291
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Benefits from antidepressants: synthesis of 6-week patient-level outcomes from double-blind placebo-controlled randomized trials of fluoxetine and venlafaxine.
    Gibbons RD; Hur K; Brown CH; Davis JM; Mann JJ
    Arch Gen Psychiatry; 2012 Jun; 69(6):572-9. PubMed ID: 22393205
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparative efficacy between venlafaxine and SSRIs: a pooled analysis of patients with depression.
    Stahl SM; Entsuah R; Rudolph RL
    Biol Psychiatry; 2002 Dec; 52(12):1166-74. PubMed ID: 12488062
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Brain functional changes (QEEG cordance) and worsening suicidal ideation and mood symptoms during antidepressant treatment.
    Hunter AM; Leuchter AF; Cook IA; Abrams M
    Acta Psychiatr Scand; 2010 Dec; 122(6):461-9. PubMed ID: 20384600
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comprehensive analysis of remission (COMPARE) with venlafaxine versus SSRIs.
    Nemeroff CB; Entsuah R; Benattia I; Demitrack M; Sloan DM; Thase ME
    Biol Psychiatry; 2008 Feb; 63(4):424-34. PubMed ID: 17888885
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Insomnia severity is an indicator of suicidal ideation during a depression clinical trial.
    McCall WV; Blocker JN; D'Agostino R; Kimball J; Boggs N; Lasater B; Rosenquist PB
    Sleep Med; 2010 Oct; 11(9):822-7. PubMed ID: 20478741
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Depression-free days as a summary measure of the temporal pattern of response and remission in the treatment of major depression: a comparison of venlafaxine, selective serotonin reuptake inhibitors, and placebo.
    Mallick R; Chen J; Entsuah AR; Schatzberg AF
    J Clin Psychiatry; 2003 Mar; 64(3):321-30. PubMed ID: 12716275
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The addition of fluoxetine to cognitive behavioural therapy for youth depression (YoDA-C): a randomised, double-blind, placebo-controlled, multicentre clinical trial.
    Davey CG; Chanen AM; Hetrick SE; Cotton SM; Ratheesh A; Amminger GP; Koutsogiannis J; Phelan M; Mullen E; Harrison BJ; Rice S; Parker AG; Dean OM; Weller A; Kerr M; Quinn AL; Catania L; Kazantzis N; McGorry PD; Berk M
    Lancet Psychiatry; 2019 Sep; 6(9):735-744. PubMed ID: 31371212
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Are there differences between serotonergic, noradrenergic and dual acting antidepressants in the treatment of depressed women?
    Eker SS; Kirli S; Akkaya C; Cangur S; Sarandol A
    World J Biol Psychiatry; 2009; 10(4 Pt 2):400-8. PubMed ID: 19670086
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Does prior antidepressant treatment of major depression impact brain function during current treatment?
    Hunter AM; Cook IA; Leuchter AF
    Eur Neuropsychopharmacol; 2012 Oct; 22(10):711-20. PubMed ID: 22445212
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.